Why David Ryan Watched Stocks That Wouldn’t Stop Rising
David Ryan would not buy a stock more than 10% above its last consolidation. Two early ANTS names show what waiting costs, and what it buys.
Explore dated articles on Position Sizing, with worked examples, hypothetical decisions and research limitations.
David Ryan would not buy a stock more than 10% above its last consolidation. Two early ANTS names show what waiting costs, and what it buys.
MRNA gapped up 84% on Phase 3 results. Compare a gap-day-low stop, O’Neil’s 8% limit and a low-volume pullback entry, with share counts and risk.
PBF hit +20% in seven sessions. Compare O’Neil’s eight-week hold with Minervini’s 50-day stop, using share counts, planned risk and what each rule gave back.
Compare CPAY entries at $406.25 and $401.10 with a $388.90 stop and $400 risk budget. Annotated charts and real calculator screenshots explain the share counts.